Endometrial polyps, clinically known as endometrial polyps, are benign endometrial lesions that can develop at any age, but are most common during childbearing years and around menopause. It can develop at any age, but is most common during childbearing years and around menopause. Hysteroscopic treatment of endometrial polyps is preferred clinically with good results, but the disease is prone to recurrence and thus appropriate measures need to be taken to prevent recurrence after hysteroscopy. The cause of recurrence of endometrial polyps is unclear and may be related to excessive endometrial hyperplasia caused by an imbalance of estrogen to progesterone ratio in the uterus. The risk of recurrence after hysteroscopic polyp removal and curettage is about 3.7-10%. To inhibit or prevent recurrence, patients who have completed childbearing or do not wish to have children in the near future may use short-acting oral contraceptives or levonorgestrel intrauterine delayed-release system. Among them, levonorgestrel intrauterine extended-release system can effectively antagonize the effect of endometrial hyperplasia, which can lead to endometrial glandular atrophy, etc., thus preventing recurrence of endometrial polyps. During the use of levonorgestrel intrauterine delayed-release system, no systemic adverse reactions will occur and the endometrial metaplasia will reduce inflammation; it will not affect the patient’s future fertility after removal and has a high safety level. In conclusion, in order to inhibit endometrial recurrence, progestogen therapy, such as the use of short-acting oral contraceptives or the levonorgestrel intrauterine delayed-release system, is mostly used after hysteroscopy.